Sickle Cell Disease
(Sickle Cell Anemia)

Article written and reviewed by Dr Luca Moretti

Sickle cell disease, also known as sickle cell anemia, is the most common inherited structural hemoglobinopathy and one of the principal monogenic diseases worldwide. It is characterized by the presence of an abnormal hemoglobin variant, hemoglobin S (HbS), responsible for the characteristic sickle deformation of red blood cells under conditions of reduced oxygen tension. This distinctive morphologic abnormality gives the disease its name and causes a complex constellation of clinical manifestations ranging from chronic hemolytic anemia and vaso-occlusive crises to ischemic or infectious organ complications.

Sickle cell disease has an extremely heterogeneous geographic distribution, with very high prevalence in sub-Saharan Africa, Mediterranean regions, the Middle East, the Indian subcontinent and the Americas, but increasing population mobility has also made the disease clinically relevant in Europe and North America. It is a major cause of childhood morbidity and mortality in the highest-incidence areas and an increasing challenge for Western healthcare systems, which must provide timely diagnosis, multidisciplinary care pathways and genetic prevention strategies.

Understanding the molecular mechanisms underlying red blood cell sickling, the distinctive pathophysiologic features and currently available diagnostic and therapeutic strategies is essential to a modern clinical and care approach capable of significantly improving prognosis.

Essential Physiologic Concepts for Understanding Sickling

In sickle cell disease, knowledge of certain fundamental principles of hemoglobin physiology and red blood cell dynamics is indispensable for understanding the basis of sickling. Under normal conditions, the red-cell membrane and cytoskeleton give red blood cells the flexibility required to pass through the narrowest capillaries and survive in the circulation, whereas the solubility of hemoglobin A (HbA) prevents intracellular polymer formation. The reversible transition of HbA between oxygenated and deoxygenated states does not cause polymerization.

In sickle cell anemia, a single point mutation in the beta-globin gene causes synthesis of HbS, a molecular variant that tends to polymerize rapidly under hypoxic conditions or reduced oxygen tension. HbS polymers form long rigid filaments that distort the red-cell membrane and give the cell its characteristic elongated sickle shape.

This process is initially reversible, but with repeated episodes of deoxygenation and polymerization, red-cell deformation becomes stable, leading to loss of normal plasticity, increased mechanical fragility and a marked tendency to obstruct the microcirculation. Progressive alteration of the cell membrane predisposes both to premature hemolysis and abnormal adhesion to endothelial cells, forming the basis of the characteristic vascular and ischemic complications.

Etiology and Genetics

The etiology of sickle cell disease is an inherited point mutation affecting the HBB gene, located on chromosome 11 and encoding the beta chain of hemoglobin. The mutation consists of substitution of a single nucleotide (adenine with thymine) at the sixth codon and causes substitution of valine for glutamic acid at position 6 of the beta chain, resulting in production of hemoglobin S (HbS).

Inheritance is autosomal recessive: the disease occurs in individuals homozygous for the mutation, HbSS, whereas heterozygotes, HbAS carriers of sickle cell trait, are generally asymptomatic; anemia in these individuals requires investigation for concomitant causes. Carriers nevertheless play a crucial role in transmission of the disease and its epidemiology.

In regions with high malaria endemicity, sickle cell trait reaches high population frequencies because of a selective advantage: HbAS heterozygotes have particularly a relative protection against severe malaria and clinical progression caused by Plasmodium falciparum, a mechanism that has favored persistence and spread of the mutation in many African, Mediterranean and Asian populations.

Genetically, sickle cell disease can also occur as a compound form when HbS coexists with other hemoglobin or thalassemia variants, such as HbC or beta-thalassemia. In these cases the clinical picture may be particularly complex and disease severity varies according to the allelic combinations present.

Pathogenesis and Pathophysiology

The pathogenesis of sickle cell disease centers on molecular and cellular abnormalities resulting from the presence of hemoglobin S in red blood cells. Under normoxic conditions HbS remains relatively stable, but when oxygen tension decreases, as physiologically occurs in the microcirculation or during systemic stress, deoxygenated HbS molecules tend to polymerize rapidly and form long polymers that aggregate within the red-cell cytoplasm.

These HbS polymers profoundly distort the red-cell membrane, which progressively assumes the characteristic sickle shape and loses deformability and plasticity. Sickled red blood cells are rigid, fragile and unable to pass easily through the narrowest capillaries. This produces two major pathologic consequences: marked chronic hemolysis, with red-cell survival reduced to approximately 10-20 days, and a tendency to obstruct the microcirculation, causing recurrent ischemia and tissue injury.

Mechanisms of vascular injury are further amplified by abnormal adhesion of sickled red blood cells to endothelium, release of inflammatory mediators and activation of coagulation. Blood stasis in microvascular beds promotes true microinfarctions, with consequent necrosis, pain and functional impairment of affected organs.

Over time, repeated vaso-occlusive crises cause chronic and irreversible lesions: renal, pulmonary, osteoarticular, ocular, cerebral and hepatic organ complications are the main cause of morbidity and mortality. Chronic hemolysis also produces chronic hemolytic anemia, compensated by increased marrow turnover and sometimes aggravated by nutritional deficiencies and increased susceptibility to infection.

Morphologically, peripheral blood shows marked anisopoikilocytosis with sickled cells, target cells and reticulocytosis. The bone marrow is hyperplastic, with increased erythroblastic activity and a tendency toward bone expansion.

In summary, the pathophysiology of sickle cell disease reflects convergence of several pathogenic processes:

• Polymerization of deoxygenated HbS and formation of rigid, poorly deformable sickled red blood cells
• Microvascular obstruction and vaso-occlusive crises with tissue ischemia and necrosis
• Chronic hemolytic anemia due to shortened red-cell survival
• Inflammatory activation and coagulation abnormalities secondary to endothelial injury

These mechanisms begin early in life and determine clinical progression of the disease and development of its multiple complications.

Classification and Epidemiology

Sickle cell disease actually comprises a spectrum of sickling syndromes that differ according to the mutation involved and the allelic combination present in hemoglobin genes. In practice, classification is based on two main parameters: genotype, meaning the mutation present and its combination with any other hemoglobin variants, and phenotype, meaning the severity and frequency of clinical manifestations. This distinction is fundamental for prognosis, therapeutic management and genetic counseling.

The principal clinical forms of sickle cell disease and, separately, sickle cell trait are:

• Classic sickle cell anemia (HbSS): the most severe and typical form, caused by homozygosity for the HbS mutation. It is associated with chronic hemolytic anemia, recurrent vaso-occlusive crises and multiorgan complications.
• Compound sickle cell disease: results from coexistence of HbS with other hemoglobin variants such as HbC, HbSC, beta-thalassemia, HbS/β-thalassemia, HbD or HbO. Severity varies according to the amount of HbS produced and the associated abnormal hemoglobin.
• Sickle cell trait (HbAS): a heterozygous carrier state distinct from sickle cell disease, characterized by a single copy of the HbS mutation. Generally asymptomatic, it may nevertheless cause manifestations under extreme hypoxia or dehydration and is an important epidemiologic factor in disease transmission.

Epidemiologically, sickle cell disease is one of the most common monogenic diseases worldwide. In 2021, approximately 515,000 births with sickle cell disease were estimated, particularly in sub-Saharan Africa, the Indian subcontinent, the Middle East, some Mediterranean regions including Sicily, the Caribbean and Brazil. The frequency of sickle cell trait may exceed 20-30% in some African populations and remains significant in many areas of the Mediterranean basin and Middle East.

The broad distribution of the HbS mutation is historically related to malaria endemicity: HbAS heterozygotes have particularly a relative protection from severe malaria and clinical progression caused by Plasmodium falciparum, explaining positive selection and persistence of the mutation in these populations. With recent migration, sickle cell disease has become an emerging problem in Europe, North America and Australia, creating new challenges in early diagnosis, complication prevention and organization of specialist care.

Increasing attention to newborn diagnosis, genetic screening programs and family counseling has led in recent years to a significant improvement in survival and quality of life in countries with advanced healthcare systems. In resource-limited areas, however, childhood mortality remains high and sickle cell disease is still one of the main causes of death during the first years of life.

Clinical Manifestations

The clinical manifestations of sickle cell disease reflect the genetic and pathophysiologic heterogeneity of the disorder and are influenced by multiple factors: genotype, circulating HbS level, presence of other hemoglobin variants, age, environmental conditions, nutritional status and access to care. The clinical picture results from the combination of chronic hemolytic anemia, recurrent vaso-occlusive crises, increased susceptibility to infection and progressive ischemic or inflammatory organ complications.

In patients with the homozygous form (HbSS), manifestations typically begin between 4 and 12 months of age, when fetal hemoglobin, HbF, decreases and HbS increases. Early symptoms include anemia with pallor, jaundice, fatigue, growth delay and reduced exercise tolerance. The painful vaso-occlusive crisis is the most characteristic complication: it presents with acute pain, typically involving long bones, joints, abdomen or chest, and may be triggered by dehydration, hypoxia, infections or metabolic stress. Frequency and severity of crises vary greatly among individuals and throughout life.

A typical presentation during the first years of life is dactylitis, or hand-foot syndrome, with painful swelling and erythema of the hands and feet due to ischemic infarction of metacarpal and metatarsal bones. As the child grows, vaso-occlusive crises may affect any skeletal or visceral site, causing bone necrosis, particularly of the femoral and humeral heads, skin ulcers, priapism, abdominal colic and, in the most severe cases, splenic sequestration, hepatic sequestration or acute chest syndrome.

Chronic hemolytic anemia is associated with persistent scleral and cutaneous jaundice, cholelithiasis, hepatomegaly and splenomegaly during the early years, frequently followed by functional autosplenectomy because of repeated splenic infarctions. Loss of splenic function exposes the patient to a very high risk of infection, particularly with encapsulated organisms, Streptococcus pneumoniae, Haemophilus influenzae, Neisseria meningitidis, which may cause fulminant sepsis and potentially fatal meningitis.

In patients with compound sickle cell disease, such as HbSC or HbS/β-thalassemia, the clinical picture is extremely variable and may range from nearly asymptomatic forms to presentations comparable to HbSS. Severity depends on the amount of HbS produced, the presence of other hemoglobin variants and concomitant environmental and clinical factors.

In carriers of sickle cell trait, HbAS, most people remain asymptomatic throughout life, but under conditions of extreme hypoxia, dehydration, intense physical exercise or reduced atmospheric pressure, transient episodes of hematuria, abdominal pain or, rarely, vaso-occlusive complications may occur. Recognition of sickle cell trait is of primary importance for prevention of severe disease in offspring and for genetic counseling.

Sickle cell trait is also associated with manifestations that do not necessarily require these triggers, including hematuria and renal papillary necrosis, increased risk of chronic kidney disease and venous thromboembolism and, very rarely, renal medullary carcinoma.

Severity of clinical manifestations and progression of sickle cell disease are strongly influenced by early diagnosis, access to specialist care and adherence to prevention and multidisciplinary follow-up programs. In high-resource countries, survival of patients with sickle cell anemia has improved markedly, whereas in areas with poor access to care mortality remains dramatically high, especially during the first years of life.

Investigations and Diagnosis

Diagnosis of sickle cell disease is based on an integrated pathway beginning with clinical and family suspicion and using hematologic, biochemical and molecular investigations. The goal is not only to identify hemoglobin S, but also to define the genetic form, disease severity, any associated variants and the presence of complications, all essential for prognosis and therapeutic and family management.

Clinical suspicion arises in the presence of chronic hemolytic anemia, recurrent painful crises, splenomegaly or a family history of hemoglobinopathies, particularly in people of African, Mediterranean, Middle Eastern or Indian origin. During the neonatal period or early childhood, dactylitis, anemia unresponsive to iron treatment, severe infectious episodes or signs of bone ischemia should prompt further diagnostic evaluation.

The first laboratory step is a complete blood count and morphologic examination of the peripheral smear. In HbSS disease, anemia is generally normocytic; microcytosis suggests coinheritance of alpha-thalassemia, HbS/beta-thalassemia or iron deficiency. Reticulocytosis, leukocytosis and thrombocytosis are also variable. The smear typically shows sickled cells, anisopoikilocytosis, target cells, circulating erythroblasts and, in the most severe cases, marked polychromasia.

Diagnostic confirmation is obtained through analysis of hemoglobin fractions by electrophoresis or HPLC, high-performance liquid chromatography, which distinguishes the various hemoglobinopathy patterns:

• In HbSS: predominance of HbS (80-95%), absence of HbA, variable HbF and variable HbA2, sometimes increased according to analytical method and genotype
• In HbAS: HbA approximately 60%, HbS approximately 40%, with normal HbA2 and HbF
• In compound forms: variable proportions of HbS, HbC, HbD, HbE or HbA according to the mutation present

In high-risk populations, newborn diagnosis through screening with rapid isoelectric focusing or HPLC has become crucial for reducing childhood mortality and planning early specialist follow-up. In atypical presentations, molecular testing, including PCR and direct sequencing, is essential for genetic definition and family counseling, allowing identification of the specific mutation and any allelic combinations.

Assessment of organ complications requires targeted investigations adapted to age, clinical picture and disease history:

• Hemolysis profile: indirect bilirubin, lactate dehydrogenase, LDH, and haptoglobin
• Renal, hepatic and cardiac function: creatinine, transaminases, echocardiography and ECG
• Imaging: bone radiographs, abdominal ultrasound and magnetic resonance imaging to assess brain or spinal cord injury
• Monitoring splenic function, with verification of vaccination status and adherence to antimicrobial prophylaxis when indicated

Organ surveillance should be adapted to age and risk: it includes at least annual renal assessment with urinalysis and testing for albuminuria/proteinuria, an annual ophthalmologic assessment for proliferative retinopathy beginning approximately at age 10 years and brain magnetic resonance imaging for silent infarcts according to age, genotype and risk profile. In asymptomatic children, echocardiography is not indicated as routine screening for pulmonary hypertension.

Identification of sickle cell trait carriers, HbAS, is of fundamental importance in prevention programs, newborn screening, premarital counseling and genetic counseling, particularly in high-risk populations and areas where different hemoglobinopathies commonly coexist.

In summary, diagnosis of sickle cell disease requires a logical sequence:

• Clinical and laboratory suspicion in the presence of chronic hemolytic anemia or recurrent vaso-occlusive crises
• Complete blood count and morphologic assessment of the peripheral smear
• Characterization of hemoglobin fractions by electrophoresis/HPLC
• Molecular analysis to define genotype and support family counseling
• Screening for organ complications and stratification of clinical risk

This diagnostic pathway makes it possible not only to recognize the disease and its variants early, but also to plan individualized and family-based therapeutic and preventive strategies.

Treatment and Prognosis

Management of sickle cell disease requires a multidisciplinary approach integrating treatment of hemolytic anemia, prevention and management of vaso-occlusive crises, treatment of organ complications, infection prevention and psychosocial and genetic support for patients and families. Treatment is highly individualized according to disease severity, age, comorbidities and access to specialist resources.

Prevention and Management of Vaso-Occlusive Crises

Painful vaso-occlusive crises are the most frequent and burdensome acute event in sickle cell disease. Management is based on:

• Adequate hydration according to clinical status, using the intravenous route when oral intake is inadequate or dehydration is present and avoiding overhydration
• Pain control with prompt analgesia titrated to severity, promptly using opioids when indicated and with frequent reassessment
• Oxygen therapy when documented hypoxia is present
• Early treatment of infections and identification of precipitating causes including fever, dehydration, hypoxia and acidosis

Blood transfusion or red blood cell exchange may be required in acute chest syndrome or other severe complications.

Disease-Modifying Therapy

The principal disease-modifying drug is hydroxyurea, which increases production of fetal hemoglobin, HbF, reducing the proportion of sickled red blood cells and the frequency of vaso-occlusive crises. Hydroxyurea has been shown to reduce mortality, hospitalizations and organ complications and is recommended for most patients with symptomatic sickle cell anemia.

In children and adolescents from 9 months to 19 years of age with sickle-cell anemia, hydroxyurea is recommended regardless of clinical severity within a specialist monitoring program.

Other strategies include chronic transfusion or red blood cell exchange in patients with neurologic complications, for secondary prevention of stroke, recurrent acute chest syndromes or inadequate response to hydroxyurea. Regular transfusions carry a risk of iron overload, which must be monitored and treated with chelation therapy, deferoxamine, deferasirox or deferiprone, according to guidelines.

To reduce alloimmunization, an extended red-cell antigen profile should be established as early as possible, ideally before the first transfusion; transfused units must be prophylactically matched at least for Rh C/c, E/e and K, in addition to ABO and RhD.

In selected cases, hematopoietic stem cell transplantation, HSCT, is an established potentially curative option, with the best outcomes in children with an HLA-identical donor and no severe organ damage. Gene and genome-editing therapies are also authorized for selected indications in some jurisdictions, with variable eligibility criteria and availability. Transplantation carries risks of rejection, infection and graft-versus-host disease and is reserved for specialist centers and carefully selected patients.

Prevention and Treatment of Complications

Follow-up includes prevention and early treatment of infections, with pneumococcal, meningococcal and Haemophilus vaccination and penicillin prophylaxis in children younger than 5 years even when vaccinated; after age 5 years it is not routine in fully vaccinated patients without additional factors, but should be considered when vaccination is incomplete, after surgical splenectomy or after previous invasive pneumococcal infection. Follow-up also includes monitoring organ function, including heart, kidneys, liver, osteoarticular system and central nervous system, assessment of growth and pubertal development, management of endocrine complications and nutritional surveillance. In children with HbSS or HbSβ0-thalassemia, periodic screening for stroke risk with transcranial Doppler is recommended, generally annually between 2 and 16 years of age.

With an abnormal TCD, in settings with adequate resources a program of regular transfusions is indicated, typically every 3-4 weeks for at least one year, with targets of HbS <30% and Hb >9 g/dL. In selected patients, after at least one year of transfusions and according to TWiTCH criteria, transition to hydroxyurea at the maximum tolerated dose may be considered.

Acute complications such as aplastic crises, acute chest syndromes, sepsis, stroke and priapism require rapid multidisciplinary intervention. In chronic or recurrent forms, including lower-limb ulcers, psychological, social and rehabilitative support is central to quality of life and school and occupational integration.

Prognosis

The prognosis of sickle cell disease has improved significantly in countries with access to early diagnosis, specialist care and prevention programs, markedly increasing survival into adulthood, although average life expectancy remains reduced and varies according to genotype, complications and access to care. The principal prognostic determinants are:

• Early diagnosis and prompt initiation of treatment
• Quality of specialist and multidisciplinary follow-up
• Adherence to disease-modifying therapies and complication-prevention programs
• Absence or good control of organ complications
• Access to advanced treatments, including transplantation and authorized gene or gene-editing therapies for selected indications

In low-income countries or settings with limited access to care, childhood mortality remains high and survivors' quality of life is often severely impaired. Gene and gene-editing therapies already authorized for selected indications offer the possibility of radical benefit to some patients, but their global impact remains limited by eligibility criteria, treatment complexity, costs and availability in specialist centers.

In conclusion, management of sickle cell disease requires constant attention to individualized treatment, complication prevention and comprehensive support for patients and families, with the goal of reducing disability and substantially improving a quality of life that remains variable and is often impaired by chronic disease.

Complications

Complications of sickle cell disease are the principal determinant of morbidity and mortality during the course of the disease, especially in patients with severe forms, early onset and inadequate control of precipitating factors. They derive from the combination of chronic hemolytic anemia, recurrent vaso-occlusive episodes, loss of splenic function and iron overload in patients receiving repeated transfusions.

Acute Complications

Acute complications are often potentially life-threatening and require prompt multidisciplinary intervention. The most important include:

• Vaso-occlusive crises: acute painful episodes involving bones, joints, abdomen or chest; they may progress to bone necrosis, visceral infarction, priapism or acute chest syndrome.
• Acute chest syndrome: characterized by chest pain, fever, tachypnea, hypoxia and pulmonary infiltrates, often associated with infections or bone-marrow fat embolism; it is a major cause of death in children and adults.
• Ischemic or hemorrhagic stroke: risk is increased in children and adults, with focal neurologic deficits, seizures or coma; after an ischemic stroke, secondary prevention with chronic transfusions is generally indicated.
• Aplastic crisis: typically triggered by Parvovirus B19 infection, with sudden reticulocytopenia and severe anemia.
• Sepsis and severe infections: particularly with encapsulated organisms following functional autosplenectomy; vaccination and antibiotic prophylaxis are required.
• Priapism: prolonged painful erection caused by obstruction of venous outflow from the corpora cavernosa, with risk of permanent injury.

Chronic Organ Complications

Chronic ischemic and inflammatory injury causes progressive and irreversible complications involving several organs:

• Musculoskeletal system: avascular necrosis of the femoral and humeral heads, osteomyelitis, chronic lower-limb ulcers, skeletal deformities and delayed bone growth.
• Central nervous system: risk of recurrent stroke, neurocognitive deficits and learning and memory disorders.
• Kidneys: isosthenuria, hematuria, proteinuria, papillary necrosis and chronic kidney failure.
• Heart and lungs: ventricular hypertrophy, cardiomyopathy, pulmonary hypertension and heart failure.
• Liver and biliary tract: chronic liver disease, cholelithiasis, cholestasis, fibrosis and cirrhosis in patients with iron overload.
• Endocrine system: delayed puberty, hypogonadism, growth disorders and, in patients with iron overload, secondary diabetes mellitus.
• Eye: proliferative retinopathy, vitreous hemorrhage, retinal detachment and blindness.

Infectious Complications

Functional or surgical asplenia creates a high risk of severe bacterial infections, especially with encapsulated organisms, pneumococcus, meningococcus and Haemophilus influenzae, with possible sepsis or meningitis. In transfused patients there also remains a risk, now very low in systems with advanced screening, of transfusion-transmitted infections, HBV, HCV and HIV; Parvovirus B19 infection may instead cause an aplastic crisis. Prevention is based on careful vaccination prophylaxis and use of antibiotics during risk periods.

Complications of Transfusion Therapy

Blood transfusions, although sometimes indispensable, may cause iron overload with hemosiderosis of the liver, heart and pancreas, risk of transmissible infections, alloimmunization and acute and chronic transfusion reactions. Iron overload should be monitored and chelation used when indicated according to iron burden and transfusion modality; with automated red blood cell exchange it may be possible to maintain neutral or negative iron balance without chelation.

Psychosocial Complications

The chronic nature of the disease, frequency of acute episodes and hospitalizations and the effects on growth and school, occupational and social integration result in an increased risk of mood disorders, anxiety, relationship difficulties and reduced quality of life for patients and families. Psychological and social support is a fundamental component of care.

Rare Complications

Less common but documented complications include noncirrhotic portal hypertension, acute renal dysfunction, hepatic crises, neurological complications due to hyperviscosity, particularly after an excessive post-transfusion hemoglobin increase, and cancer risk, especially hepatocellular carcinoma in patients with iron overload and viral hepatitis.

Early identification and integrated management of both acute and chronic complications are central to follow-up in specialist sickle cell centers and are crucial to improving prognosis and quality of life.

References
1. Rees DC, Williams TN, Gladwin MT. Sickle-cell disease. Lancet. 2010;376(9757):2018–2031.
2. Piel FB, Steinberg MH, Rees DC. Sickle Cell Disease. N Engl J Med. 2017;376(16):1561–1573.
3. Kato GJ, Piel FB, Reid CD, et al. Sickle cell disease. Nat Rev Dis Primers. 2018;4:18010.
4. Yawn BP, Buchanan GR, Afenyi-Annan AN, et al. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. JAMA. 2014;312(10):1033–1048.
5. Ware RE, de Montalembert M, Tshilolo L, et al. Sickle cell disease. Lancet. 2017;390(10091):311–323.
6. Vichinsky EP, Neumayr LD, Earles AN, et al. Causes and outcomes of the acute chest syndrome in sickle cell disease. N Engl J Med. 2000;342(25):1855–1865.
7. DeBaun MR, Armstrong FD, McKinstry RC, et al. Silent cerebral infarcts: a review on a prevalent and progressive cause of neurologic injury in sickle cell anemia. Blood. 2012;119(20):4587–4596.
8. Niihara Y, Miller ST, Kanter J, et al. A phase 3 trial of L-glutamine in sickle cell disease. N Engl J Med. 2018;379(3):226–235.
9. Bender MA, Carlberg K. Sickle Cell Disease. GeneReviews®. Updated 2025.
10. DeBaun MR, Jordan LC, King AA, et al. American Society of Hematology 2020 guidelines for sickle cell disease: prevention, diagnosis, and treatment of cerebrovascular disease in children and adults. Blood Adv. 2020;4(8):1554–1588.
11. Brandow AM, Carroll CP, Creary S, et al. American Society of Hematology 2020 guidelines for sickle cell disease: management of acute and chronic pain. Blood Adv. 2020;4(12):2656–2701.
12. U.S. Food and Drug Administration. CASGEVY prescribing information and approval information. Accessed 2026.
13. U.S. Food and Drug Administration. LYFGENIA prescribing information and approval information. Accessed 2026.